Equities

Anteotech Ltd

Anteotech Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.021
  • Today's Change-0.001 / -4.55%
  • Shares traded183.51k
  • 1 Year change-30.00%
  • Beta1.5799
Data delayed at least 20 minutes, as of Sep 20 2024 06:46 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Anteotech Ltd grew revenues 26.85% from 405.90k to 514.89k while net income improved from a loss of 12.65m to a smaller loss of 8.88m.
Gross margin--
Net profit margin-1,724.74%
Operating margin-2,468.84%
Return on assets-120.47%
Return on equity-231.19%
Return on investment-159.35%
More ▼

Cash flow in AUDView more

In 2024, Anteotech Ltd increased its cash reserves by 84.76%, or 2.31m. Cash Flow from Financing totalled 9.89m or 1,919.89% of revenues. In addition the company used 6.52m for operations while cash used for investing totalled 1.06m.
Cash flow per share-0.0035
Price/Cash flow per share--
Book value per share0.0022
Tangible book value per share0.0022
More ▼

Balance sheet in AUDView more

Anteotech Ltd appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio3.04
Quick ratio--
Total debt/total equity0.4399
Total debt/total capital0.3055
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.